Cera™ ASD Occluder Post-Market Clinical Follow-Up Study

Exclusion Criteria

• •Patients who have extensive congenital cardiac anomaly which can only be adequately repaired by cardiac surgery.
• •Patients who have sepsis within one month prior to implantation, or any systemic infection that can't be successfully treated prior to device placement.
• •Patients known to have a bleeding disorder, untreated ulcer or any other contraindications to aspirin therapy, unless another anti-platelet agent can be administered for 6 months.
• •Patients who have demonstrated intra-cardiac thrombi on echocardiography (especially left atrial or left atrial appendage thrombi).
• •Patients whose size (i.e., too small to tolerate TEE probe, catheter size, etc.) or condition (active infection, etc.) would cause the patient to be a poor candidate for cardiac catheterization.
• •Patients where the margins of the defect are less than 5mm from the coronary sinus, AV valves or right upper lobe pulmonary vein.
• •Patients did not conduct any follow up visit after hospital discharge.